Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye Drops
A Multicenter, Prospective, Intervention Study on the Control of Myopia in Young Children Using High-order Phase Element Array Microstructure Lenses (H.O.P.E.) in Combination With Low-concentration Atropine Eye Drops (0.02%)
A multicenter, prospective, intervention study on the control of myopia in young children using high-order phase element array microstructure lenses (H.O.P.E.) in combination with low-concentration atropine eye drops (0.02%)
調査の概要
状態
条件
詳細な説明
This study focused on 6-9-year-old young children as the research subjects, aiming to investigate 1. The effectiveness of using H.O.P.E. lenses alone and in combination with 0.02% atropine eye drops, in order to provide data support and clinical guidance for the clinical effectiveness and safety of the high-order phase unit (H.O.P.E.) array microstructure lenses in young children with myopia.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Meinan He
- 電話番号:13672135765
- メール:hmn509@tmu.edu.cn
研究場所
-
-
-
Tianjin、中国
- Tianjin Medical University Eye Hospital
-
コンタクト:
- Meinan He
- 電話番号:13672135765
- メール:hmn509@tmu.edu.cn
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age: 6-9 years old (6 years old but under 10 years old), gender not restricted;
- Clinically diagnosed with bilateral myopia (after cycloplegia), refractive error within -6.00D < SER ≤ -0.50D, astigmatism ≤ 1.50D, refractive anisometropia ≤ 1.50D (based on subjective refraction values);
- Corrected visual acuity LogMAR ≤ 0.1;
- Able to understand the research purpose, voluntarily participate, and the subject and his/her legal guardian sign the informed consent form.
Exclusion Criteria:
If a subject meets any of the following exclusion criteria, they will not be included in this study:
- Those who have discontinued the use of atropine eye drops (due to glaucoma or a tendency towards glaucoma, or are allergic to scopolamine or the components of this product);
- Those currently suffering from any of the following diseases that may affect vision or refractive errors, or ocular organic diseases: such as diseases causing damage to the lens like cataracts, glaucoma, macular degeneration, corneal diseases, uveitis, retinal detachment, severe vitreous opacity, acute/chronic keratitis, conjunctivitis, irregular cornea, keratoconus, manifest strabismus, fundus diseases, etc.; systemic diseases that may affect the eyes, such as immune system diseases, central nervous system diseases, Down syndrome, asthma, epilepsy, severe heart or lung function disorders, severe liver or kidney function impairments, etc.;
- Those who have participated in other clinical trials or studies related to myopia control within 90 days before signing the informed consent form;
- Those who have used myopia control products within 90 days before signing the informed consent form (such as near-axial lenses, low-concentration atropine eye drops, corneal reshaping lenses, red light, etc.);
- Those who cannot wear glasses regularly or use the medication as required (such as having a significant difference in compliance);
- During the screening period, the intraocular pressure of either eye is greater than 21 mmHg or less than 10 mmHg, or the intraocular pressure difference between both eyes is ≥ 5 mmHg;
- There is a severe abnormality in the accommodative function (accommodative amplitude < 8D);
- Only one eye meets the inclusion criteria;
- Other situations that the researcher deems unsuitable for participating in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Group A (H.O.P.E. Lens Group)
Wearing H.O.P.E. lens frame glasses (provided by Shenyang Kangnd Medical Technology Co., Ltd.) |
Wear the H.O.P.E. lens frame glasses and use the placebo. Use it once per night for both eyes. |
|
アクティブコンパレータ:Group B (0.02% Atropine group)
Use 0.02% atropine sulfate eye drops (provided by Shenyang Xingqi Eye Pharmaceuticals Co., Ltd.) |
Wear single-vision frame glasses and use 0.02% atropine sulfate eye drops twice a day, once at night for both eyes. |
|
実験的:Group C (H.O.P.E. lenses + 0.02% atropine group)
Wearing H.O.P.E. lens frame glasses (provided by Shenyang Kangnd Medical Technology Co., Ltd.); Use 0.02% atropine sulfate eye drops (provided by Shenyang Xingqi Eye Pharmaceuticals Co., Ltd.) |
Wear the H.O.P.E. lens frame glasses and use the placebo. Use it once per night for both eyes. Wear single-vision frame glasses and use 0.02% atropine sulfate eye drops twice a day, once at night for both eyes. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
The final spherical equivalent refractive error (SER) measured by cycloplegic refraction combined with both automated and subjective refraction after 12 months of wearing glasses, compared with the baseline value.
時間枠:From enrollment to the end of treatment at 12 months
|
From enrollment to the end of treatment at 12 months
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
The change in AL (axial length) from the baseline after wearing the glasses for 12 months
時間枠:From enrollment to the end of treatment at 12 months
|
From enrollment to the end of treatment at 12 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ruihua Wei、Tianjin Medical University Eye Hospital
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。